Most patients with Alzheimer's disease present with amnestic problems; however, a
substantial proportion, over-represented in young-onset cases, have atypical phenotypes …

Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and
functional decline associated with age together with a particular neuropathology. It was first …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Aducanumab has been approved by the US Food and Drug Administration for treatment of
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …

Brain clocks, which quantify discrepancies between brain age and chronological age, hold
promise for understanding brain health and disease. However, the impact of diversity …

Plasma amyloid-β (Aβ) 42, phosphorylated tau (p-tau) 181, and neurofilament light chain
(NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these …

Background and Objectives To evaluate whether plasma biomarkers of amyloid
(Aβ42/Aβ40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light …

Importance Racial and ethnic groups with higher rates of clinical Alzheimer disease (AD) are
underrepresented in studies of AD biomarkers, including amyloid positron emission …

Introduction Although dementia prevalence differs by race, it remains unclear whether
cognition and neuropsychiatric symptom severity differ between Black and White individuals …

Research on racial differences in Alzheimer disease (AD) dementia has increased in recent
years. Older African American individuals bear a disproportionate burden of AD and …